ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS) Announces Major Developments in HAE Treatment

Introduction

Pharvaris, a leading biopharmaceutical company, has recently unveiled plans for the groundbreaking CHAPTER-3 Phase 3 study of deucrictibant extended-release tablets. This study aims to revolutionize the prophylactic treatment of hereditary angioedema (HAE) attacks, while also introducing new hope for patients suffering from acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH).

Key Developments

Pharvaris has announced the initiation of the pivotal Phase 3 study, CHAPTER-3, which focuses on the use of deucrictibant extended-release tablets as a prophylactic treatment for HAE. This marks a significant milestone in the field of biopharmaceuticals, as this novel approach could provide unprecedented relief for patients battling these debilitating conditions.

In addition to their groundbreaking work with HAE, Pharvaris has also revealed their intention to explore the clinical development of deucrictibant in the treatment of AAE-C1INH. This new indication opens up exciting possibilities for patients suffering from this rare condition, offering hope where previously there was little to be found.

Differentiating Characteristics of Deucrictibant

Pharvaris has presented a robust data set highlighting the unique features of deucrictibant that set it apart from other treatment options. The efficacy, safety profile, and convenience of the extended-release tablets make them a promising contender in the fight against HAE and AAE-C1INH.

Impact on Individuals

For individuals living with HAE or AAE-C1INH, the developments announced by Pharvaris offer new hope for improved quality of life. The potential for a more effective and convenient treatment option could mean fewer attacks, less severe symptoms, and a greater sense of control over these chronic conditions.

Global Implications

On a global scale, the advancements in HAE and AAE-C1INH treatment brought about by Pharvaris could have far-reaching implications. Improved management of these conditions could lead to reduced healthcare costs, decreased disability rates, and a higher quality of life for patients worldwide.

Conclusion

Pharvaris’ announcement of the CHAPTER-3 Phase 3 study and the exploration of deucrictibant for AAE-C1INH treatment mark a significant step forward in the field of biopharmaceuticals. These developments have the potential to transform the lives of individuals with HAE and AAE-C1INH, while also making a positive impact on a global scale. The future looks brighter for those affected by these rare conditions, thanks to the innovative work being done by Pharvaris.